Suche

Bosch Healthcare Solutions develops the first patient device for asthmatics

Bosch Healthcare Solutions develops the first patient device for asthmatics

  • Premiere of Vivatmo me, the world’s first patient device for measuring FeNO concentration, at MEDICA 2016 in Düsseldorf, the world’s largest medical technology trade fair.
  • The Vivatmo system makes it possible for the first time to monitor the treatment of patients with asthma even more closely.
  • Regular breath gas analysis improves control of the disease, helping to op-timize treatment and improve compliance.

Waiblingen, Germany – Bosch Healthcare Solutions is presenting the world’s first patient device for asthmatics at MEDICA 2016 (November 14-17 in Düsseldorf). Vivatmo me measures the concentration of fractional exhaled nitric oxide (FeNO) in people with chronically inflamed airway diseases, such as allergic asthma. The FeNO concentration is a direct indicator of the degree of inflammation in eosinophilic airway diseases.(1) Patients can use Vivatmo me to monitor their treatment themselves, and can provide their physician with valuable information about the course of the disease and their response to treatment. This enables close monitoring of the patient’s condition and, if necessary, a rapid adjustment of treatment. The Vivatmo system consists of Vivatmo pro, the device for physicians; Vivatmo me, the device for patients; and a Vivatmo app, developed especially for the patient device. This app wirelessly transmits the measured data via Bluetooth to the patient’s smartphone, from where the information can be sent to the attending physician. When used in conjunction with the measurements made by Vivatmo pro, Vivatmo me’s non-invasive technique can also help lower the exacerbation rate of asthma and in turn possibly reduce the administration of anti-inflammatory medication for this chronic condition, such as inhaled corticosteroids.(2)

FeNO as a biomarker for eosinophilic airway inflammation

Even before a lung function test, an elevated FeNO concentration indicates a worsening of the condition and thus makes it possible to prescribe treatment to counteract it early on.(1) The American Thoracic Society (ATS) and other bodies recommend determining the FeNO concentration in expiratory airflow.(1) FeNO is highly accurate in predicting the (non-)responsiveness of inflammatory mediators on glucocorticoids.(1) Reduced need for medication as well as the avoidance of misdiagnosis, severe exacerbation of the disease, and acute emergency measures could improve the cost-effectiveness of asthma treatment.(3)

Considerable benefit – and not just for physicians

Vivatmo me lets patients direct assess their own treatment for the first time. Using a procedure that is easy to integrate into their daily routine, patients can regularly measure their FeNO at home – similar to diabetics monitoring their blood sugar – and thereby objectively monitor their asthma. They learn to detect early on which individual factors improve or worsen their asthma. In turn, this can lead to a more confident and conscientious way of dealing with the condition.

Vivatmo pro was specially developed for use in clinical practice and, thanks to its simple measuring procedure and intuitive operation, is optimized for integration into clinical routines. This means physicians can be more effective in their everyday clinic work, enabling them to further improve the personalized treatment of patients. The Vivatmo pro device for physicians stands out from the competition in that it is wireless, requires no maintenance, and is simpler to operate. Working with the FeNO biomarker makes patient treatment more efficient, allowing a doctor’s practice to save up to 160 euros per patient per year, depending on the severity of the asthma.(4)The Vivatmo system gives both doctor and patient more control over the disease. All Vivatmo devices are produced entirely within Germany.

About allergic asthma

Asthma is a chronic inflammatory disease of the airways of the lungs, characterized by bronchial hypersensitivity in conjunction with a constriction of the airways. It is one of the most common chronic conditions. Some 5 percent of adults suffer from asthma, and 10 percent of children have it, making it the most common chronic condition in that group.(5) An allergic reaction is the cause of asthma in up to 80 percent of cases.(6) Symptoms range from a feeling of tightness in the chest to severe shortness of breath. They may be present constantly or occur in connection with environmental factors (such as pollen dispersal). Treatment options include drug (e.g. corticosteroids) and non-drug measures (e.g. patient education, respiratory physiotherapy).

Tags: Healthcare

Sources

(1) Dweik RA et al., Am J Respir Crit Care Med. 2011;184:602-15

(2) Syk J. et al., J Allergy Clin Immunol Pract 2013;1:639–48

(3) Harnan SE et al., Health Technol Assess. 2015;19:1-330

(4) Berg J., Lindgren P., Respir Med. 2008;102:219-31

(5) National Disease Management Guidelines for Asthma; short version, 2nd edition, version 5, December 2009 (last amended: August 2013)

Contact person for press inquiries:
Christiane Wild-Raidt
Phone: +49 711 811-6283

Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH. The subsidiary was established in 2015 with the aim of developing products and services that improve people’s health and quality of life. More than 80 associates are currently employed at the company’s headquarters in Waiblingen, Germany (2016). The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

More information is available online at www.bosch-healthcare.com/en/

The Bosch Group is a leading global supplier of technology and services. It employs roughly 402,000 associates worldwide (as of December 31, 2017). The company generated sales of 78.1 billion euros in 2017. Its operations are divided into four business sectors: Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology.

As a leading IoT company, Bosch offers innovative solutions for smart homes, smart cities, connected mobility, and connected manufacturing. It uses its expertise in sensor technology, software, and services, as well as its own IoT cloud, to offer its customers connected, cross-domain solutions from a single source. The Bosch Group’s strategic objective is to deliver innovations for a connected life. Bosch improves quality of life worldwide with products and services that are innovative and spark enthusiasm. In short, Bosch creates technology that is “Invented for life.” The Bosch Group comprises Robert Bosch GmbH and its roughly 440 subsidiary and regional companies in 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. The basis for the company’s future growth is its innovative strength. At 125 locations across the globe, Bosch employs some 64,500 associates in research and development.

Additional information is available online at www.bosch.com, www.iot.bosch.com, www.bosch-press.com, www.twitter.com/BoschPresse.

Still looking for something?